AKT1 and ovarian carcinoma: We would expect that cancers with activation of the PI3K/AKT pathway may not respond well to common chemotherapy, as overexpression of activated AKT decreases apoptosis induced by paclitaxel in ovarian cancer cells [81] and introduction of the catalytic subunit of PI3K into ovarian cancer cells causes resistance to paclitaxel [82].